As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Regeneron Pharmaceuticals: Wolverine Trading LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., Nomura Holdings Inc., Millennium Management LLC, Laurion Capital Management LP, Group One Trading LLC, Eisler Capital Management Ltd., D. E. Shaw & Co. Inc., Cresset Asset Management LLC, Cubist Systematic Strategies LLC, Caption Management LLC, Centiva Capital LP, Capstone Investment Advisors LLC, Citadel Advisors LLC, Balyasny Asset Management L.P., Bank of America Corp DE, BNP Paribas Financial Markets, Jane Street Group LLC, Tudor Investment Corp ET AL, Parallax Volatility Advisers L.P., Two Sigma Securities LLC, Susquehanna International Group LLP, Hsbc Holdings PLC, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Trading LLC, Walleye Capital LLC, Barclays PLC, Capital Fund Management S.A., Capula Management Ltd, National Bank of Canada FI, JPMorgan Chase & Co., Mirae Asset Securities USA Inc., Simplex Trading LLC, NINE MASTS CAPITAL Ltd, Garda Capital Partners LP, Allianz Asset Management GmbH, Covenant Asset Management LLC, IMC Chicago LLC, XR Securities LLC, SG Americas Securities LLC, and JPMorgan Chase & Co.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.